@Dustyboots
bascially they have trial data for 12+ but they're waiting and seeing what counties vaccining this age group pick up - like blood clots being picked up only during the mass vaccination and not the trials.
How dreadful for kids being experimented on in these countries.
To get the licensed in UK pharmaceutical companies had to hold trials with childlren in 12-18 age range. The teens and their parents will have had a variety of reasons to take part and would have been fully briefed.
It's why there isn't going to be a vaccine for under 12 any time soon in UK as there hasn't been any been trials with the vaccines UK uses done with chidren this young.
When you vaccinate a wider population and in greater numbers than in trials additional usually rarer problems can be spotted - it's why many countries with low covid rates earlier in year said they were waiting and watch what happened in counrties like UK who due to high covid rates were rolling out mass vaccination programs.
Essentailly we now doing same with 12-18 group - waiting on more data fro other countries. We can do this because our adult vaccination program has gone really well with little vaccine hesitacy - in Wales 75% of adults under 50 have been vaccinated already with one dose. By mid August 70% of the entire population of UK will be double vaccinated.
The risk benefit in UK for 12-18 is clearly finely balanced and the group looking at it wants more data - as a parent I want them to have all the data they need to make the best decsion for my children and their peers.
If I was in another part of the world - like a red state in US with high covid levels and low vaccine uptake the risk/benefit calculation is going to be differnet and tehre are cleare rbenefits to vaccination. The US is one of the places that vacciante 12-18 years olds and one of the places we are waiting data from.
I'm unclear who you think is "being experimeneted on " - these countries have taken decsions based on their situations as have the children and parents in those counrties. If data from them helps the JMCI clarify the risk benefit to UK chidren I really can't see why this is a bad thing.